Prostate-specific antigen and radiation therapy for clinically localized prostate cancer

International Journal of Radiation Oncology, Biology, Physics

Volumn 32, Issue 2, 1995, Pages 293-306

  Zagars, Gunar K ^a   Pollack, Alan ^a   Kavadi, Vivek S ^a   von Eschenbach, Andrew C ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Multivariate analysis; Prognostic factors; Prostate cancer; Prostate specific antigen; Radiation therapy

Indexed keywords

BIOCHEMICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; DIAGNOSTIC VALUE; DRUG BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; TREATMENT OUTCOME; TUMOR LOCALIZATION;

AGED; AGED, 80 AND OVER; FOLLOW-UP STUDIES; HUMAN; MALE; MIDDLE AGE; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0029035171     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/0360-3016(95)00077-C     Document Type: Article

References (41)

1. The incidence of monotone likelihood in the Cox model
2. Pathologic factors that influence prognosis in stage A prostatic cancer: The influence of extent vs. grade
3. PSA velocity for the diagnosis of early prostate-cancer. A new concept
4. Is prostate specific antigen of clinical improtance in evaluating outcome after radical prostatectomy
5. The prognostic significance of DNA ploidy in clinically localized prostate cancer treated with radiation therapy
6. Localized prostate carcinoma. Surgical management
7. Prostatic-specific antigen confirmation of long term cure of prostate cancer treated by external beam radiation in the RTOG
8. Prostate specific antigen after external beam radiotherapy for prostate cancer: Followup
9. Serum prostatespecific antigen after radiation therapy for clinically localized prostate cancer: Prognostic implications
10. The effect of overall treatment time on the outcome of definitive radiotherapy for localized prostate carcinoma: The Radiation Therapy Oncology Group 75-06 and 77-06 experience
11. Incidental carcinoma of the prostate: An analysis of the predictors of progression
12. Pelvic lymphadenectomy for staging clinically localized prostate cancer: Indications, complications, and results in 217 cases
13. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years
14. Prostatespecific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer
15. Near-diploidy: A new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy
16. Prostate-specific antigen doubling time and disease relapse after radiotherapy for prostate cancer
17. Relationship of tumor DNA-ploidy to serum prostatespecific antigen doubling time after radiotherapy for prostate cancer
18. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer
19. Estimation of confidence limits for the cumulative probability of survival in life table analysis
20. Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate
21. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume
22. Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: I. Untreated patients
23. The value of serial prostate-specific antigen determinations 5 years after radiotherapy: Sleeply increasing values characterize 80% of patients
24. Prostate-specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer
25. The hazard of accelerated tumor clonogen repopulation during radiotherapy
26. Prostatespecific antigen and external beam radiotherapy in prostate cancer
27. Prostate-specific antigen as a prognostic factor for prostate cancer treated with external beam radiotherapy
28. Prostate specific antigen: An important marker for prostate cancer treated by external beam radiation therapy
29. The fall and rise of prostatespecific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer
30. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy
31. The T classification of clinically localized prostate cancer. An appraisal based on disease outcome following radiation therapy
32. Early androgen ablation for stage D1 (N1–N3, M0) prostate cancer. Prognostic variables and outcome
33. The prognostic importance of Gleason grade in prostatic adenocarcinoma: A long-term follow-up study of 648 patients treated with radiation therapy
34. Prostate-specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy
35. Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate-specific antigen value as a predictor of treatment outcome